Cargando…
Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma
Cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGFR), has been successfully used to treat some patients with colorectal cancer and those with head and neck squamous cell carcinoma (HNSCC). For the effective treatment, it is essential to first identify cetuximab-respon...
Autores principales: | Kondo, T, Ozawa, S, Ikoma, T, Yang, X-Y, Kanamori, K, Suzuki, K, Iwabuchi, H, Maehata, Y, Miyamoto, C, Taguchi, T, Kiyono, T, Kubota, E, Hata, R-I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399171/ https://www.ncbi.nlm.nih.gov/pubmed/27399917 http://dx.doi.org/10.1038/oncsis.2016.43 |
Ejemplares similares
-
C-X-C Motif Chemokine Ligand 14 is a Unique Multifunctional Regulator of Tumor Progression
por: Yang, Xiao-Yan, et al.
Publicado: (2019) -
Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice
por: Hata, Ryu-Ichiro, et al.
Publicado: (2015) -
Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer
por: Sjöberg, Elin, et al.
Publicado: (2016) -
CXCL14: the Swiss army knife chemokine
por: Benarafa, Charaf, et al.
Publicado: (2015) -
A New Strategy to Find Targets for Anticancer Therapy: Chemokine CXCL14/BRAK Is a Multifunctional Tumor Suppressor for Head and Neck Squamous Cell Carcinoma
por: Hata, Ryu-Ichiro
Publicado: (2012)